Stress myocardial scintigraphy and dobutamine echocardiography in the detection of coronary disease in asymptomatic patients with type 2 diabetes

Diabetes and Metabolism

Volumn 31, Issue 2, 2005, Pages 135-142

  Le Feuvre, C I ^a   Barthelemy O ^a   Dubois Laforgue, D ^b   Maunoury, Ch ^c   Mogenet, A ^b   Baubion, N ^c   Metzger, J P ^a   Timsit, J ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Grp Hosp Pitie Salpetriere ^*  (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Diabetes mellitus; Dobutamine echocardiography; Myocardial scintigraphy; Silent myocardial ischemia

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ATENOLOL; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPYRIDAMOLE; DOBUTAMINE; LINSIDOMINE; THALLIUM 201;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BEHAVIOR MODIFICATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DOBUTAMINE ECHOCARDIOGRAPHY; DOPPLER FLOWMETRY; ECHOCARDIOGRAPHY; EQUIPMENT; FEMALE; GENDER; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; RISK FACTOR; SCINTIGRAPHY; SILENT MYOCARDIAL INFARCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS MYOCARDIAL SCINTIGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 17744364328     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70179-9     Document Type: Article

References (25)

1. Vanzetto G, Halimi S, Hammoud T et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Diabetes Care, 1999, 22, 19-26.
2. Marwick TH, Case C, Sawada S, Vasey C, Short L, Lauer M. Use of stress echocardiography to predict mortality in patients with diabetes and known or suspected coronary artery disease. Diabetes Care, 2002, 25, 1042-8.
3. Giri S, Shaw LJ, Murthy DDR et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary srtery disease. Circulation, 2002, 105, 32-40.
4. Sozzi FB, Elhendy A, Roclandt et al. Prognostic value of dobutamine stress echocardiography in patients with diabetes. Diabetes Care, 2003, 26, 1074-8.
5. Penfornis A, Zimmermann C, Boumal D et al. Use of dobutamine stress echocardiography in detecting silent myocardial ischaemia in asymptomatic diabetic patients: a comparison with thallium scintigraphy and exercise testing. Diabet Med, 2001, 18, 900-5.
6. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care, 1998, 21, 1551-9.
7. Puel I, Valensi P, Vanzetto G et al. Identifying myocardial ischacmia in diabetics. SFC/ALFEDI AM guidelines. Arch Mal Ceur, 2004, 97, 338-57.
8. Deedwania PC. Is there evidence in support of the ischemia suppression hypothesis? J Am Coll Cardiol, 1994, 24, 21-4.
9. Wackers FJ, Zaret BL. Detection of myocardial ischemia in patients with diabetes mellitus. Circulation, 2002,105, 5-7.
10. Diabetes mcllitus: report of a WHO study group. WHO Tech Rep Ser, 1985, 727, 1-113.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron, 1976, 16, 31-41.
12. Schiller NB, Shah PM, Crawford M. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr, 1989, 2, 358-67.
13. Ganau A, Devercux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol, 1992, 19, 1550-60.
14. Geleijnse ML, Fioretti PM, Roelandt JR. Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol, 1997, 30, 595-606.
15. Le Feuvre C, Baubion N, Auhry N, Metzger JP, de Vernejoul P, Vacheron A. Assessment of reversible clyssynergic segments utter myocardial infarction: dobutamine echocardiography versus thallium-201 single photon emission computed tomography. Am Heart J, 1996, 131, 668-75.
16. Lafont A, Dubois-Rande JL, Steg PG, et al. The French Randomized Optimal Stenting Trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. FROST study group. J Am Coll Cardiol, 2000, 36, 404-9.
17. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial ischemia in patients with diabetes. Who to screen. Diabetes Care, 1999, 22, 1396-400.
18. Valensi P, Sachs RN, Lormeau B, et al. Silent myocardial ischaemia and left ventricle hypertrophy in diabetic patients. Diabetes Metab, 1997, 23, 409-16.
19. Schinkel AFL, Bax JJ, Geleijnse ML, et al. Noninvasive evaluation of ischaemic heart disease: myocardial perfusion imaging or stress echcardiography. Eur Heart J, 2003, 24, 789-800.
20. Beller GA, Gibson RS. Sensitivity, specificity and prognostic significance of non-invasive testing for occult or known coronary disease. Prog Cardiovasc Dis. 1987, 23, 241-70.
21. Nitemberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and Ach-induced coronary vasodilatation in diabetic patients with angiographically normal coro-nary arteries and normal left ventricular systolic function. Diabetes, 1993, 42, 1017-25.
22. Nahser PJ, Brown RE, Oskarsson H. Winniford M, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilatation in patients with diabetes mellitus. Circulation, 1995, 91, 635-40.
23. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation, 1994, 90, 762-8.
24. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up. Outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation, 1997, 95, 2037-43.
25. Gaede P, Vedel P, Larsen N, Jensen GV, Pairing HH, Peclersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-93.